Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biden Says Administration Working With Vaccine Manufacturers on Contingency Plans to Combat New Variant

11/29/2021 | 12:51pm EST

By Tarini Parti

President Biden said his administration was working with officials at Pfizer Inc., Moderna Inc. and Johnson & Johnson to develop contingency plans for vaccines or boosters in case they are needed to combat the Omicron variant of the coronavirus.

Mr. Biden said at this time officials don't think such additional measures will be needed.

He also said he will soon release a strategy outline for how the administration plans to deal with Covid-19 this winter, adding that the plans would focus on more vaccinations, boosters and testing rather than lockdowns.

"This variant is a cause for concern, not a cause for panic," he said.

Write to Tarini Parti at tarini.parti@wsj.com

(END) Dow Jones Newswires

11-29-21 1251ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -3.17% 156.53 Delayed Quote.-39.28%
JOHNSON & JOHNSON -0.80% 165.25 Delayed Quote.-3.40%
MODERNA, INC. -3.76% 167.52 Delayed Quote.-34.04%
PFIZER, INC. 0.95% 54.05 Delayed Quote.-8.47%
All news about MODERNA, INC.
01/20Moderna says aims to name 'country of choice' for COVID vaccine production in Africa so..
RE
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
01/20EMA : Assessment of whether vaccination can cause capillary leak syndrome (is ongoing for ..
RE
01/19Prior COVID infection more protective than vaccination during Delta surge, U.S. study f..
RE
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
01/18US Stocks Slump as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on Financials
MT
01/18US Stocks Start Week Lower as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on ..
MT
01/18Morgan Stanley Adjusts Moderna Price Target to $315 From $313, Maintains Equal Weight R..
MT
01/18Equities Slump Midday After Treasury Yields Touch Two-Year High, Goldman's Earnings Mis..
MT
01/18MIDDAY REPORT : US Stocks Slump After Treasury Yields Touch Two-Year High; Goldman's Earni..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 520 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,35x
Yield 2021 -
Capitalization 67 921 M 67 921 M -
EV / Sales 2021 3,32x
EV / Sales 2022 2,23x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 167,52 $
Average target price 273,19 $
Spread / Average Target 63,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831
CELLTRION, INC.-16.67%19 342